Anti-angiogenic therapy as treatment for benign uterine disorders
OwnerArjan Willem GRIFFIOEN, Judith Anne Francisca HUIRNEinventors
Life of this patent
Estimating the term…
Abstract
The disclosure provides methods and devices for the treating or preventing a benign uterine disorder in a female mammalian subject. The methods comprise administering a non-steroidal angiogenesis inhibitor. Such methods and devices are particularly useful for treating women suffering from adenomyosis and related symptoms.
Claims15
A non-steroidal angiogenesis inhibitor for use in treating or preventing a benign uterine disorder in a female mammalian subject, comprising locally administering to a subject in need thereof said non-steroidal angiogenesis inhibitor.
The inhibitor for use of any of the preceding claims, wherein the non-steroidal angiogenesis inhibitor is administered intra-uterine.
The inhibitor for use of any one of the preceding claims, wherein the non-steroidal angiogenesis inhibitor is provided by an intra-uterine device (IUD).
The inhibitor for use of any one of the preceding claims, wherein the non-steroidal angiogenesis inhibitor is provided as an extended-release formulation or via a extended-release IUD.
The inhibitor for use of any one of the preceding claims, wherein the female mammalian subject is a human.
An intra-uterine device comprising a non-steroidal angiogenesis inhibitor.
The inhibitor for use or the intra-uterine device of any of the preceding claims, where in the angiogenesis inhibitor is a small molecule or an antigen binding molecule such as an antibody or antigen binding fragment thereof.
The inhibitor for use or the intra-uterine device of any of the preceding claims, wherein the angiogenesis inhibitor targets an angiogenic signaling axis, e.g. VEGF, VEGF receptor, EGF, EGF receptor, PDGF, PDGF receptor, or PGF, PGF receptor.
The inhibitor for use or the intra-uterine device of any of the preceding claims, wherein the angiogenesis inhibitor targets an angiogenesis-associated molecule or receptor, e.g. an integrin, CD36, CD44, extracellular vimentin, fibrillin-2, secreted frizzled-related protein-2, lysyl oxidase, prostate specific membrane antigen, versican, apelin.
The inhibitor for use or the intra-uterine device of any of the preceding claims, wherein the angiogenesis inhibitor is an anti-VEGF binding molecule such as an antibody or antigen binding fragment thereof, a peptibody or a nanobody.
Dependencies are inferred from the claim text.